2

The power of phase II end-points for different possible mechanisms of action of an experimental treatment

*European Journal of Cancer* 2015; 51(8):984-992

Using transcriptomics to guide lead optimization in drug discovery projects: Lessons learned from the QSTAR project

*Drug Discovery Today* 2015; 20(5):505-513

Re: Hilton P, Bryant A, Howel D, McColl E, Buckley BS, Lucas MG, et al. Assessing professional equipoise and views about a future clinical trial of invasive urodynamics prior to surgery for stress urinary incontinence in women: A survey within a mixed methods feasibility study. Neurourol Urodyn. 2012;31(8):1223–30

*Neurourology and Urodynamics* 2016; 35(6):750-751

Comparison of socio-economic indicators explaining inequalities in Healthy Life Years at age 50 in Europe: 2005 and 2010

*European Journal of Public Health* 2015; 25(6):978–983

CHRNA5 risk variant predicts delayed smoking cessation and earlier lung cancer diagnosis—A meta-analysis

*JNCI: Journal of the National Cancer Institute* 2015; 107(5):djv100

Inconsistent treatment estimates from mis‐specified logistic regression analyses of randomized trials

*Statistics in Medicine* 2015; 34(19):2681-2694

Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer

*Cochrane Database of Systematic Reviews* 2015; 4:CD010260

What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?

Life expectancy with and without cognitive impairment in seven Latin American and Caribbean countries

*PLoS ONE* 2015; 10:e0121867

Independent replication of a melanoma subtype gene signature and evaluation of its prognostic value and biological correlates in a population cohort

*Oncotarget* 2015; 6(13):11683-11693